drugset / Trial / NCT05681377

Impact of Flumazenil on the Emergence Delirium

NCT05681377

Phase 4 Completed 68 enrolled Korea University Guro Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

Flumazenil rapidly antagonizes benzodiazepines (BZDs); it may induce agitation, seizure, or delirium, especially when applied to patients who have taken BZDs for a long time. On the contrary, it may help patients regain consciousness in a stable and calm state by appropriately reversing the central nervous system depressant effects of BZDs. In this study, we aim to investigate the impact of flumazenil on the emergence delirium in patients anesthetized with remimazolam, the short-acting BZD drug.

Timeline

Start
2023-03-05
Primary completion
2023-08-11
Completion
2023-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Flumazenil Small molecule 0.2 mg Intravenous

Indications

No indication recorded.